Cantor Fitzgerald analyst Charles Duncan initiates coverage on Cognition Therapeutics (NASDAQ:CGTX) with a Overweight rating and announces Price Target of $12.
Cantor Fitzgerald analyst Charles Duncan initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Overweight rating and announces Price Target of $41.